Literature DB >> 7165698

Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin.

J J Holst.   

Abstract

Enteroglucagon (II) was isolated from extracts of pig ileum mucosa by repeated gel filtrations, and its immunochemical and chromatographic characteristics were compared with those of a synthetic peptide corresponding to the 33-69 sequence of pig glicentin, before and after digestion with trypsin or trypsin followed by carboxypeptidase B, by using five region-specific assays covering most of the glicentin sequence. Enteroglucagon (II) and the synthetic peptide behave identically under three different conditions of chromatography as determined with all five assays (including a highly specific radioreceptor assay), and gave rise to similar fragments after enzyme digestion. It was therefore concluded that enteroglucagon (II) and the 33-69 sequence of glicentin are most probably identical.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7165698      PMCID: PMC1153876          DOI: 10.1042/bj2070381

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  10 in total

1.  A radioreceptor-assay for glucagon: binding of enteroglucagon to liver plasma membranes.

Authors:  J J Holst
Journal:  Diabetologia       Date:  1975-06       Impact factor: 10.122

2.  Purification and characterization of a protein from porcine gut with glucagon-like immunoreactivity.

Authors:  F Sundby; H Jacobsen; A J Moody
Journal:  Horm Metab Res       Date:  1976-09       Impact factor: 2.936

3.  Purification of 125 I-glucagon by anion exchange chromatography.

Authors:  K H Jorgensen; U D Larsen
Journal:  Horm Metab Res       Date:  1972-05       Impact factor: 2.936

4.  Evidence for transformation of glucagon-like immunoreactivity of gut into pancreatic glucagon in vivo.

Authors:  L Korányi; F Péterfy; J Szabó; A Török; M Guóth; G Tamás
Journal:  Diabetes       Date:  1981-09       Impact factor: 9.461

5.  Heterogeneity of somatostatin like immunoreactivity (SLI) in extracts of porcine, canine and human pancreas.

Authors:  C B Newgard; J J Holst
Journal:  Acta Endocrinol (Copenh)       Date:  1981-12

6.  Evidence that glicentin contains the entire sequence of glucagon.

Authors:  J J Holst
Journal:  Biochem J       Date:  1980-05-01       Impact factor: 3.857

7.  Relationship of glicentin to proglucagon and glucagon in the porcine pancreas.

Authors:  A J Moody; J J Holst; L Thim; S L Jensen
Journal:  Nature       Date:  1981-02-05       Impact factor: 49.962

Review 8.  Extrapancreatic glucagons.

Authors:  J J Holst
Journal:  Digestion       Date:  1978       Impact factor: 3.216

9.  Extraction, gel filtration pattern, and receptor binding of porcine gastrointestinal glucagon-like immunoreactivity.

Authors:  J J Holst
Journal:  Diabetologia       Date:  1977-04       Impact factor: 10.122

10.  The primary structure of porcine glicentin (proglucagon).

Authors:  L Thim; A J Moody
Journal:  Regul Pept       Date:  1981-05
  10 in total
  48 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

2.  Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial.

Authors:  Mette Marie H Christensen; Kurt Højlund; Ole Hother-Nielsen; Tore B Stage; Per Damkier; Henning Beck-Nielsen; Kim Brøsen
Journal:  Diabetologia       Date:  2015-08-14       Impact factor: 10.122

Review 3.  Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

Authors:  J J Holst
Journal:  Diabetologia       Date:  2006-01-14       Impact factor: 10.122

4.  Potent inhibitory effects of transplantable rat glucagonomas and insulinomas on the respective endogenous islet cells are associated with pancreatic apoptosis.

Authors:  N Blume; J Skouv; L I Larsson; J J Holst; O D Madsen
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

5.  Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

Authors:  M A Nauck; N Kleine; C Orskov; J J Holst; B Willms; W Creutzfeldt
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

6.  Effect of glicentin-related peptides on glucagon secretion in anaesthetized dogs.

Authors:  A Ohneda; T Kobayashi; J Nihei
Journal:  Diabetologia       Date:  1986-06       Impact factor: 10.122

7.  The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.

Authors:  Kristine J Hare; Tina Vilsbøll; Meena Asmar; Carolyn F Deacon; Filip K Knop; Jens J Holst
Journal:  Diabetes       Date:  2010-02-11       Impact factor: 9.461

8.  The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men.

Authors:  K Pilgaard; C B Jensen; J H Schou; V Lyssenko; L Wegner; C Brøns; T Vilsbøll; T Hansen; S Madsbad; J J Holst; A Vølund; P Poulsen; L Groop; O Pedersen; A A Vaag
Journal:  Diabetologia       Date:  2009-03-14       Impact factor: 10.122

9.  Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes.

Authors:  P V Højberg; M Zander; T Vilsbøll; F K Knop; T Krarup; A Vølund; J J Holst; S Madsbad
Journal:  Diabetologia       Date:  2008-02-22       Impact factor: 10.122

10.  The T-allele of TCF7L2 rs7903146 associates with a reduced compensation of insulin secretion for insulin resistance induced by 9 days of bed rest.

Authors:  Amra C Alibegovic; Mette P Sonne; Lise Højbjerre; Torben Hansen; Oluf Pedersen; Gerrit van Hall; Jens J Holst; Bente Stallknecht; Flemming Dela; Allan Vaag
Journal:  Diabetes       Date:  2010-01-27       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.